LAS VEGAS — New-onset psoriasis occurred more frequently in children with inflammatory bowel disease who received anti-TNF biologic therapy than it did in their counterparts who did not receive biologics, according to a presenter at the Crohn’s & Colitis Congress.

“New autoimmune disorders were noted approximately once every 100 patient years in the anti-TNF biologics cohort and were significantly more common compared to the nonbiologics cohort,” Richard Colletti, MD, of the University of Vermont Children’s Hospital in Burlington, Vermont, said during his presentation. “New autoimmune disorders do arise in anti-TNF biologics-treated pediatric IBD patients but overall are uncommon and not serious.”